The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Deep multi-omic analyses to identify targetable pathways in desmoplastic small round cell tumor (DSRCT) with opportunities for clinical intervention.
 
Limin Zhu
No Relationships to Disclose
 
Jamie Keck
No Relationships to Disclose
 
Jayne Stommel
No Relationships to Disclose
 
Brett Johnson
No Relationships to Disclose
 
Christopher L. Corless
Employment - Omics Data Automation
Stock and Other Ownership Interests - Guardant Health; Omics Data Automation
Consulting or Advisory Role - Cepheid
Patents, Royalties, Other Intellectual Property - Royalties on a patent for a fertility treatment
 
Christopher W. Ryan
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Daiichi Sankyo; Exelixis; Partner Therapeutics; Synox
Research Funding - Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline/Novartis (Inst); Karyopharm Therapeutics (Inst); Leducq (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xynomic Pharma (Inst)
 
Gordon B. Mills
Stock and Other Ownership Interests - Bluedot; Catena; ImmunoMET; Nuvectis Pharma; SignalChem; Tarveda Therapeutics; Turbine
Honoraria - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Consulting or Advisory Role - Amphista Therapeutics; Astex Pharmaceuticals; AstraZeneca; BlueDot; Chrysalis biotherapeutics; Ellipses Pharma; GlaxoSmithKline; ImmunoMET; Infinity Pharmaceuticals; Ionis Pharmaceuticals; Leapfrog Bio; Lilly; MedaCorp; NanoString Technologies; Nuvectis Pharma; PDX Pharmacy; Qureator; Roche; SignalChem; Symphogen; Tarveda Therapeutics; Turbine; Zentalis
Research Funding - Adelson Medical Research Foundation; AstraZeneca; Breast Cancer Research Foundation; Genentech; GlaxoSmithKline; ImmunoMET; Komipharm; Lilly; NanoString Technologies; Ovarian Cancer Research Foundation; Prospect Creek Foundation
Patents, Royalties, Other Intellectual Property - DSP technology patent with Nanostring; HRD assay to Myriad Genetics
Travel, Accommodations, Expenses - AstraZeneca; Chrysalis Biomedical Advisors; ImmunoMET; Michigan Primary Care Consortium; Pfizer; Symphogen
 
Lara E. Davis
Consulting or Advisory Role - Daiichi Sankyo; Regeneron; SpringWorks Therapeutics
Research Funding - Bayer (Inst); BTG (Inst); Eisai (Inst); Novartis (Inst)